Olivia Gardner

1.2k total citations
22 papers, 929 citations indexed

About

Olivia Gardner is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Olivia Gardner has authored 22 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Olivia Gardner's work include Cancer Immunotherapy and Biomarkers (6 papers), Adenosine and Purinergic Signaling (4 papers) and Peroxisome Proliferator-Activated Receptors (4 papers). Olivia Gardner is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Adenosine and Purinergic Signaling (4 papers) and Peroxisome Proliferator-Activated Receptors (4 papers). Olivia Gardner collaborates with scholars based in United States, South Korea and Canada. Olivia Gardner's co-authors include Lee M. Graves, Brian J. Dewar, Ching-Shih Chen, Douglas J. DeMarini, Danièle Ouellet, James M. Samet, H. Shelton Earp, Chung-Wai Shiau, Jeffrey R. Infante and Leslie A. Fecher and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Olivia Gardner

21 papers receiving 914 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Olivia Gardner United States 13 669 407 136 113 102 22 929
Julie C. Lougheed United States 12 571 0.9× 259 0.6× 78 0.6× 168 1.5× 109 1.1× 16 998
Christian Borgo Italy 18 702 1.0× 224 0.6× 86 0.6× 59 0.5× 70 0.7× 38 991
Katayoun I. Amiri United States 11 490 0.7× 318 0.8× 156 1.1× 49 0.4× 183 1.8× 20 746
Scott Wise United States 17 660 1.0× 293 0.7× 195 1.4× 179 1.6× 161 1.6× 43 1.2k
Tim P. Green United Kingdom 13 699 1.0× 504 1.2× 59 0.4× 159 1.4× 133 1.3× 14 1.2k
Sheila Miknyoczki United States 14 548 0.8× 398 1.0× 61 0.4× 104 0.9× 113 1.1× 19 1.1k
Jangsoon Lee United States 18 684 1.0× 434 1.1× 84 0.6× 90 0.8× 166 1.6× 40 1.1k
Michele Dowless United States 15 597 0.9× 280 0.7× 98 0.7× 109 1.0× 100 1.0× 26 871
Christophe Frémin France 15 650 1.0× 201 0.5× 69 0.5× 62 0.5× 107 1.0× 17 1.0k
Derek L. Dai Canada 14 629 0.9× 292 0.7× 179 1.3× 56 0.5× 115 1.1× 18 1.0k

Countries citing papers authored by Olivia Gardner

Since Specialization
Citations

This map shows the geographic impact of Olivia Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivia Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivia Gardner more than expected).

Fields of papers citing papers by Olivia Gardner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivia Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivia Gardner. The network helps show where Olivia Gardner may publish in the future.

Co-authorship network of co-authors of Olivia Gardner

This figure shows the co-authorship network connecting the top 25 collaborators of Olivia Gardner. A scholar is included among the top collaborators of Olivia Gardner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivia Gardner. Olivia Gardner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sachdev, Jasgit C., Amy Prawira, Arvind Chaudhry, et al.. (2021). Abstract PS12-12: Efficacy and safety of AB928 plus pegylated liposomal doxorubicin (PLD) with or without IPI-549 in participants with metastatic ovarian and triple negative breast cancer. Cancer Research. 81(4_Supplement). PS12–12. 4 indexed citations
2.
3.
Spira, Alexander I., Paul Conkling, Melissa L. Johnson, et al.. (2020). ARC-4 study: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology. 38(15_suppl). e21659–e21659. 9 indexed citations
4.
5.
6.
Becerra, Carlos, Andrew Scott Paulson, Gulam A. Manji, et al.. (2019). Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results from a dose escalation.. Journal of Clinical Oncology. 37(4_suppl). 283–283. 12 indexed citations
7.
Ouellet, Danièle, Nastya Kassir, Samer Mouksassi, et al.. (2016). Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemotherapy and Pharmacology. 77(4). 807–817. 42 indexed citations
8.
Simpkins, Fiona, Aurea E. Flores, Christina Chu, et al.. (2013). Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study. Cancer Immunology Research. 1(3). 168–178. 41 indexed citations
9.
Robertson, Michael J., Justin Kline, Herbert Struemper, et al.. (2013). A Dose-Escalation Study of Recombinant Human Interleukin-18 in Combination With Rituximab in Patients With Non-Hodgkin Lymphoma. Journal of Immunotherapy. 36(6). 331–341. 29 indexed citations
10.
Gandara, David R., Sandrine Hiret, George R. Blumenschein, et al.. (2013). Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. Journal of Clinical Oncology. 31(15_suppl). 8028–8028. 23 indexed citations
11.
Kelly, Karen, Julien Mazières, Fabrice Barlési, et al.. (2013). Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. Journal of Clinical Oncology. 31(15_suppl). 8027–8027. 36 indexed citations
12.
Kim, Kevin B., Richard Kefford, Anna C. Pavlick, et al.. (2012). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology. 31(4). 482–489. 356 indexed citations
13.
Becerra, Carlos, Jeffrey R. Infante, Lawrence Garbo, et al.. (2012). A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 3023–3023. 10 indexed citations
14.
15.
Robertson, Michael J., John W. Bauman, Olivia Gardner, et al.. (2011). Phase I Trial Evaluating the Safety and Biological Activity of Iboctadekin (rhIL-18) in Combination with Rituximab in Patients with CD20+ B Cell Non-Hodgkin's Lymphoma,. Blood. 118(21). 3697–3697. 1 indexed citations
16.
Dewar, Brian J., Olivia Gardner, Ching-Shih Chen, et al.. (2007). Capacitative Calcium Entry Contributes to the Differential Transactivation of the Epidermal Growth Factor Receptor in Response to Thiazolidinediones. Molecular Pharmacology. 72(5). 1146–1156. 21 indexed citations
17.
Yohe, Marielle E., Kent L. Rossman, Olivia Gardner, et al.. (2007). Auto-inhibition of the Dbl Family Protein Tim by an N-terminal Helical Motif. Journal of Biological Chemistry. 282(18). 13813–13823. 40 indexed citations
18.
Gardner, Olivia, Brian J. Dewar, & Lee M. Graves. (2005). Activation of Mitogen-Activated Protein Kinases by Peroxisome Proliferator-Activated Receptor Ligands: An Example of Nongenomic Signaling. Molecular Pharmacology. 68(4). 933–941. 87 indexed citations
19.
Gardner, Olivia, Chung-Wai Shiau, Ching-Shih Chen, & Lee M. Graves. (2005). Peroxisome Proliferator-activated Receptor γ-independent Activation of p38 MAPK by Thiazolidinediones Involves Calcium/Calmodulin-dependent Protein Kinase II and Protein Kinase R. Journal of Biological Chemistry. 280(11). 10109–10118. 83 indexed citations
20.
Gardner, Olivia, Brian J. Dewar, H. Shelton Earp, James M. Samet, & Lee M. Graves. (2003). Dependence of Peroxisome Proliferator-activated Receptor Ligand-induced Mitogen-activated Protein Kinase Signaling on Epidermal Growth Factor Receptor Transactivation. Journal of Biological Chemistry. 278(47). 46261–46269. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie C. Lougheed Breakdown of academic impact, for papers by Christian Borgo Breakdown of academic impact, for papers by Katayoun I. Amiri Breakdown of academic impact, for papers by Scott Wise Breakdown of academic impact, for papers by Tim P. Green Breakdown of academic impact, for papers by Sheila Miknyoczki Breakdown of academic impact, for papers by Jangsoon Lee Breakdown of academic impact, for papers by Michele Dowless Breakdown of academic impact, for papers by Christophe Frémin Breakdown of academic impact, for papers by Derek L. Dai
Rankless by CCL
2026